Filing Flows › Lemaitre Vascular (LMAT) › Q2 2026
Lemaitre Vascular (LMAT) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 5, 2026
Lemaitre Vascular (LMAT) reported revenue of $70.4M for the second quarter 2026 (Q2 2026), +10% from a year earlier and +6% from the quarter before. Operating margin was 29.0%, net earnings $17.1M (24.2% of revenue).
Lemaitre Vascular, Q2 2026: revenue $70.4M (+10% year over year), operating margin 29.0%, net earnings $17.1M, operating cash flow $16.0M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $70.4M | +6% | +10% |
| Gross profit | $50.8M | +5% | +13% |
| Operating profit | $20.4M | +15% | +26% |
| Net earnings | $17.1M | +9% | +24% |
| Operating cash flow | $16.0M | +6% | -21% |
| Free cash flow | $13.7M | +11% | -28% |
What changed
Revenue was $70.4M in Q2 2026, up 10% year over year and up 6% from the previous quarter.
Gross margin was 72.1%, up 2.1 points from Q2 2025. Operating profit was $20.4M, a 29.0% margin (up 3.9 points year over year). Of the extra revenue versus Q2 2025, 69% reached operating profit, above the 25% margin then. Operating expenses grew 5% against revenue growth of 10%. The fastest-growing cost line was Research & development (+37%). Net earnings were $17.1M, up 24% year over year. The effective tax rate was 23.2%.
Operating cash flow was $16.0M (down 21% year over year), 94% of net earnings. Non-cash charges added back $2.7M of depreciation and amortization and $1.9M of share-based compensation. Working capital and other items used $5.7M. Capital expenditures of $2.3M left free cash flow of $13.7M.
Questions
What was Lemaitre Vascular's revenue in the second quarter 2026?
Lemaitre Vascular (LMAT) reported revenue of $70.4M for the second quarter 2026 (Q2 2026), +10% from a year earlier and +6% from the quarter before.
Was Lemaitre Vascular profitable in the second quarter 2026?
Operating profit was $20.4M (29.0% of revenue) and net earnings $17.1M.
Source: Lemaitre Vascular 10-Q on SEC EDGAR.